1) Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med. 1985 Apr;102(4):458-65.
2) Chan A.K., Han S.J., Choy W. Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. Clin Neuropathol. Sep/Oct 2017;36(5):213-221
3) Pilarski R., Carlo M., Cebulla C., et al, editors. BAP1 Tumor Predisposition Syndrome In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. 2016 Oct 13 [updated 2020 Sep 17.
4) Black J.O. Xeroderma Pigmentosum Head Neck Pathol. 2016 Jun;10(2):139-44. Epub 2016 Mar 14.
5) Yang Q., Sheng Yi., Mengting L. Genetic analyses of oculocutaneous albinism types 1 and 2 with four novel mutations. BMC Med Genet. 2019 Jun 13;20(1):106.
6) Lee S. Duffy D.L. McClenahan P. Lee K.J. McEniery E. Burke B. et al. Heritability of naevus patterns in an adult twin cohort from the Brisbane Twin Registry: a cross-sectional study. Br J Dermatol. 2016; 174: 356-363.
7) Alikhan, A., et al. Congenital melanocytic nevi: where are we now? Part I. Clinical presentation, epidemiology, pathogenesis, histology, malignant transformation, and neurocutaneous melanosis // J Am Acad Dermatol. 2012 Oct;67(4):495.e1-17. doi: 10.1016/j.jaad.2012.06.023
8) Delaunay, J., et al. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3 // JAMA Dermatol. 2017;153(11):1122-1129. doi:10.1001/jamadermatol.2017.2926
9) Ibrahimi, O. A., et al. Congenital melanocytic nevi: where are we now? Part II. Treatment options and approach to treatment // J Am Acad Dermatol. 2012 Oct;67(4):515.e1-13. doi: 10.1016/j.jaad.2012.06.022
10) Potjer, T. P., et al. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families // Int J Cancer. 2019 May 15;144(10):2453-2464. doi: 10.1002/ijc.31984
11) Potrony, M., et al. Update in genetic susceptibility in melanoma // Ann Transl Med. 2015 Sep; 3(15): 210. doi: 10.3978/j.issn.2305-5839.2015.08.11
12) Rossi, M., et al. Familial Melanoma: Diagnostic and Management Implications // Dermatol Pract Concept. 2019 Jan 31;9(1):10-16. doi: 10.5826/dpc.0901a03
13) Toussi, A., et al. Germline mutations predisposing to melanoma // J Cutan Pathol. 2020 Jul;47(7):606-616. doi: 10.1111/cup.13689
14) Price HN, Schaffer JV. Congenital melanocytic nevi-when to worry and how to treat: Facts and controversies. Clin Dermatol. 2010 May-Jun;28(3):293-302
15) Piepkorn M, Meyer LJ, Goldgar D, Seuchter SA, Cannon-Albright LA, Skolnick MH, Zone JJ. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. J Am Acad Dermatol. 1989 Mar;20(3):407-15.
16) Alikhan A, Ibrahimi OA, Eisen DB. Congenital melanocytic nevi: where are we now? Part I. Clinical presentation, epidemiology, pathogenesis, histology, malignant transformation, and neurocutaneous melanosis. J Am Acad Dermatol. 2012 Oct;67(4):495.e1-17; quiz 512-4
17) Greene, M.H. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi / M.H. Greene, W.H. Clark Jr., M.A. Tucker et al. // Ann Intern Med. – 1985. – №102. – P. 458–465
18) Fusaro, R.M. The FAMMM syndrome: epidemiology and surveillance strategies / R.M. Fusaro, H.T. Lynch // Cancer Invest. – 2000. – № 18 – P. 670–680
19) Rat, C., et al., Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study. BMJ Open, 2015. 5(7): p. e007471.
20) Gandini, S., et al., Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer, 2005. 41(1): p. 28-44.
21) Gandini, S., et al., Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer, 2005. 41(1): p. 45-60.
22) Gandini, S., et al., Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer, 2005. 41(14): p. 2040-59.
23) Dinnes, J., et al., Visual inspection for diagnosing cutaneous melanoma in adults. Cochrane Database Syst Rev, 2018. 12(12): p. Cd013194.
24) Clebak, K.T., L. Helm, and M. Helm, Accuracy of Dermoscopy vs. Visual Inspection for Diagnosing Melanoma in Adults. Am Fam Physician, 2020. 101(3): p. 145-146.
25) Coit DG, Thompson JA, Albertini M, Algazi A, Andtbacka R, Bichakjian C, Carson WE, 3rd, Daniels GA, DiMaio D, Fields RC et al: NCCN Clinical Practice Guidelines in Oncology. Melanoma. Version 3.2018. In.: National Comprehensive Cancer Network, Inc; 2018: 172
26) Sawicka, E., et al., Giant congenital melanocytic nevi: selected aspects of diagnostics and treatment. Med Sci Monit, 2015. 21: p. 123-32.
27) Fledderus, A.C., et al., Outcomes and measurement instruments used in congenital melanocytic naevi research: A systematic review. J Plast Reconstr Aesthet Surg, 2020. 73(4): p. 703-715
28) Watts, C.G., et al., Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. Br J Dermatol, 2015. 172(1): p. 33-47.
29) Stapleton, J.L., et al., Correspondence between pigmented lesions identified by melanoma patients trained to perform partner-assisted skin self-examination and dermatological examination. Cancer Epidemiol Biomarkers Prev, 2015. 24(8): p. 1247-53.